Rare Infectious Disease News
Advertisement
Spotlight On
Ebola virus disease
Ebola virus disease (EVD) is a deadly disease with occasional outbreaks that occur mostly on the African continent
Prevalence
<1 >
Age of Onset
ICD-10
A98.4
Inheritance
This condition does not appear to have a clear pattern of inheritance.
5 Facts you should know
FACT
A viral hemorrhagic fever in humans and other primates, caused by ebolaviruses
FACT
Symptoms typically start anywhere between two days and three weeks after becoming infected with the virus
FACT
The first symptoms are usually fever, sore throat, muscle pain, and headaches
FACT
These are usually followed by vomiting, diarrhea, rash and decreased liver and kidney function, at which point, some people begin to bleed both internally and externally
FACT
The disease kills between 25% and 90% of those infected—about 50% on average
Interest over time
Google searches
Top Clinical Trials
| Title | Description | Phases | Status | Interventions | More Information |
|---|---|---|---|---|---|
| Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Years and in Their Adults and/or Children Relatives Living in Lambaréné, Gabon | LA rVSVΔG-ZEBOV-GP -02-PED is a Phase 1/2, randomized, controlled open label trial. The LA rVSVΔG-ZEBOV-GP -02-PED trial aims primarily to assess the clinical significance of shedding of the rVSV RNA following vaccination with the rVSVΔG-ZEBOV-GP vaccine in children. | Phase 1|Phase 2 | Recruiting | Biological: rVSVΔG-ZEBOV-GP, V920 | More Info |
| An Open Study of the Safety and Pharmacokinetics of a Drug for the Emergency Prevention of Ebola Virus Disease | Open-label safety, tolerability, pharmacokinetics and immunogenicity study in three dose escalation groups | Phase 1 | Recruiting | Drug: Gamezumab | More Info |
| A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women | The purpose of this study is: a) to assess adverse maternal/fetal outcomes in pregnant women randomized to receive the 2- dose Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo [Group A]) and in control women (unvaccinated pregnant women [Group B]); | Phase 3 | Recruiting | Biological: Ad26.ZEBOV|Biological: MVA-BN-Filo | More Info |
Top Treatments in Research
| Agent | Class/Mechanism of Action | Development Status | Company | Clinical Studies | More Information |
|---|---|---|---|---|---|
| rVSVΔG-ZEBOV-GP, V920 (Erbevo) | ERVEBO is a replication-competent, live, attenuated recombinant vesicular stomatitis virus (rVSV) vaccine | Phase 1/2 | Centre de Recherche Médicale de Lambaréné Collaborator: Merck Sharp & Dohme Corp. | More Info | n/a |
| Gamezumab | Monoclonal antibodies against Ebola virus disease | Phase 1 | Gamaleya Research Institute of Epidemiology and Microbiology | More Info | More Info |
| Ad26.ZEBOV|Biological: MVA-BN-Filo | Adenovirus serotype 26 encoding the ebola virus mayinga glycoprotein (Ad26.ZEBOV) | Phase 3 | Janssen Vaccines & Prevention B.V. | More Info | n/a |